The presence of biCEBPA mutations was associated with a higher rate of de novo AML, a higher hemoglobin level, lower platelet count and lower frequencies of additional mutations of NPM1, FLT3-TKD or the presence of FLT3-ITD. This evidence concerns the gene NPM1 and acute myeloid leukemia.